SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥145.53+CN¥2.64 (+1.85%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 16.17% below the high.
Loading market information…
SHZ · 000028.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:12 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
China National Accord Medicines Corporation Ltd.’s quoted price sits in the lower half of its reported 52-week range, 15.64% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
China National Accord Medicines Corporation Ltd.’s forward annual dividend is CN¥0.62 per share, paid annual. The forward yield is 2.93% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
China National Accord Medicines Corporation Ltd.’s next earnings report is currently expected on Apr 14, 2027, with estimated earnings per share of CN¥0.36. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow China National Accord Medicines Corporation Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
China National Accord Medicines Corporation Ltd. primarily focuses on the wholesale and retail distribution of a wide array of pharmaceutical and medical products. The company's extensive product offerings include traditional Chinese remedies, advanced biochemical and biological medicines, diagnostic agents, and antibiotics. Additionally, it supplies various chemical preparations, food items, industrial chemicals, and a diverse range of other general commodities. Beyond its core sales activities, the company is involved in selling medical apparatus and instruments. It offers comprehensive logistics services, encompassing freight transportation, warehousing, and cargo handling, alongside professional consulting. Further diversifying its operations, it markets glassware, cosmetics, and daily necessities, and provides goods agency services. The firm also participates in the import and export of technology, leases properties, and engages in the wholesale and retail of health-related products. As of December 31, 2021, China National Accord Medicines managed a significant network of 8,798 drugstores across 20 provinces, autonomous regions, and municipalities within China. This expansive retail footprint included 7,257 directly owned stores and 1,541 franchised locations. Established in 2004 and based in Shenzhen, China, the company operates as a subsidiary of Sinopharm Group Co., Ltd.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| CN¥18.33B-31.33% vs estimate |
| Q2 2025 | Aug 14, 2025 | CN¥0.61+19.84% vs estimate | CN¥18.50B-24.9% vs estimate |
|---|
| Q1 2025 | Apr 25, 2025 | CN¥0.59+6.31% vs estimate | CN¥18.29B-10.9% vs estimate |
|---|
| Q4 2024 | Mar 18, 2025 | -CN¥0.76-224.79% vs estimate | CN¥17.91B-35.07% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥145.53+CN¥2.64 (+1.85%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 16.17% below the high.
CN¥49.03+CN¥0.41 (+0.84%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.52% below the high.
HK$51.30+HK$0.65 (+1.28%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 36.63% below the high.
CN¥16.50+CN¥0.07 (+0.43%)
Shanghai Pharmaceuticals Holding Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 11.1% below the high.
CN¥27.99+CN¥0.21 (+0.76%)
China National Medicines Corporation Ltd.’s quoted price sits in the lower half of its reported 52-week range, 10.23% below the high.
CN¥8.86-CN¥0.01 (-0.11%)
China Meheco Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.53% below the high.
CN¥24.49+CN¥1.78 (+7.84%)
Qingdao Baheal Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.88% below the high.
CN¥9.98+CN¥0.22 (+2.25%)
Zhejiang Int'l Group Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.5% below the high.
